2-Ethyl-5-methyl-piperidin | 71185-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Ethyl-5-methyl-piperidin
• 英文别名: 2-ethyl-5-methyl-piperidine；2-Aethyl-5-methyl-piperidin；2-Ethyl-5-methylpiperidine
• CAS: 71185-82-5
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: GNXGHNXLUPRSCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Ethyl-5-methyl-piperidin 生成 2-ethyl-1-(3,5-dinitro-benzoyl)-5-methyl-piperidine
  参考文献：
  名称：

  Jacobs; Craig, Journal of Biological Chemistry, 1938, vol. 124, p. 659,664

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙基-5-甲基吡啶 在 溶剂黄146 、 铂 作用下， 生成 2-Ethyl-5-methyl-piperidin
  参考文献：
  名称：

  Jacobs; Craig, Journal of Biological Chemistry, 1938, vol. 124, p. 659,664

  摘要：

  DOI：

文献信息

• Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof
  申请人：ADAMS Christopher

  公开号：US20160152605A1

  公开（公告）日：2016-06-02

  The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式I的化合物：(I)，一种用于制造本发明化合物的方法，并且本发明化合物具有治疗作用，可作为替代途径补体的抑制剂，特别是因子B的抑制剂。本发明还提供了一种药理活性剂的组合和一种制药组合物。
• LIQUID CRYSTALLINE MEDIUM
  申请人：Merck Patent GmbH

  公开号：EP1658352B1

  公开（公告）日：2008-04-02
• LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY
  申请人：Merck Patent GmbH

  公开号：EP1824946B1

  公开（公告）日：2009-09-30
• UREA DERIVATIVES AND USES THEREOF
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US20170129876A1

  公开（公告）日：2017-05-11

  The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
• US4334073A
  申请人：——

  公开号：US4334073A

  公开（公告）日：1982-06-08